Hycult Biotech/C3b/iC3b，人，单克隆抗体3E7，功能研究抗体，低内毒素/HM2286-FS/0.5 mg
商品编号：
HM2286-FS
品牌：
hycultbiotech
市场价：
¥18020.00
美元价：
10812.00
产品分类：
标签抗体
公司分类：
Tag_antibody
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
Description:C3b/iC3b,Human,mAb3E7,functionalstudyantibody,lowendotoxin
Monoclonalantibody3E7recognizeshumancomplementC3b/iC3bandblocksactivationofthealternativepathway(AP).Thecomplementsystemplaysimportantrolesinbothinnateandadaptiveimmuneresponseandcanproduceaninflammatoryandprotectivereactiontochallengesfrompathogensbeforeanadaptiveresponsecanoccur.Therearethreepathwaysofcomplementactivation.TheclassicalpathwayisinitiatedbyImmunecomplexes;thelectinpathwaybysurfaceboundmannanbindinglectin;andtheAPbyallthesurfacesthatarenotspecificallyprotectedagainstit.EachgeneratesaC3convertase,aserineproteasethatcleavesthecentralcomplementproteinC3,andgeneratesthemajorcleavagefragmentC3b.TheC3andC5convertasesareenzymaticcomplexesthatinitiateandamplifytheactivityofthecomplementpathwaysandultimatelygeneratethecytolyticMAC.UponactivationofC3twofragmentsaregenerated.ThesmalleranaphylatoxinC3aandthelargershortlivedC3b.Thelatterishighlyreactiveandcanbindtocomplement-activatingparticlesorimmune-complexes.Unliketheclassicalpathway,theAPisinstateofcontinuousactivation.TheAPplaysanimportantroleintissuesdamageandinflammationassociatedwithcertainautoimmunediseasesandwithischemia-reperfusioninjury.IncreasingevidencesuggestsblockingactivationofAPcanpreventorreducecertaindiseasepathologiesandmaintainhostdefenseaffordedbyCPandLP.DepositionofC3boncellsurfacescanopsonizecellsfordestruction.CellboundC3bcanbedegradedtoinactiveforms,iC3bandthenC3dg.Antibody3E7showsenhancedspecificityforC3b(i)attachedtoacellsurfaceanditcanbindtoC3b(i)-opsonizedcellsinwholeblood.TheantibodyblocksAPbasedonitscapacitytopreventC3bdepositiononthesurfaceofavarietyAPactivatorsandalsoinhibitsAP-promotedlysisofrabbiterythrocytes,asusedinthestandardAP50test.Clone3E7competeswithfactorBandHforbindingtoC3b-opsonizedsubstrates.Theuseof3E7hasbeenshowntoenhancetheimmunotherapeuticactionofRituximab.TheCPisnotaffectedorenhancedbythisantibody.
Specifications:
| Catalognumber | HM2286-FS |
|---|---|
| Producttype | Monoclonalantibodies |
| Quantity | 0.5mg |
| Formulation | 0.5mgof0.2μmfilteredantibodysolutioninPBS(exactconcentrationisindicatedonthelabel). |
| Application | Flowcytometry,Functionalstudies,Immunofluorescence |
| ApplicationNotes | mAb3E7blocksthealternativepathwayandnottheclassicalpathway(Ref5). |
| Use | Thetypicalstartingworkingdilutionis1:50.Forfunctionalstudies,invitrodilutionshavetobeoptimizedinuser’sexperimentalsetting. |
| Immunogen | C3b(i)-Sepharose |
| Isotype | MouseIgG1 |
| Species | Human |
| References | 1.Kennedy,Aetal;Ananti-C3b(i)mAbenhancescomplementactivation,C3b(i)depositionandkillingofCD20cellsbyrituximab.Blood2003,101:3 2.Kennedy,Aetal;RituximabinfusionpromotesrapidcomplementdepletionandacuteCD20lossinChronicLymphocyticLeukemia.JournalofImmunology2004,172:5 3.Pawluczkowycz,Aetal;Hematinpromotescomplementalternativepathway-mediateddepositionofC3activationfragmentsonhumanerythrocytes:Potentialimplicationsforthepathogenesisofanemiainmalaria.JournalofImmunology2007,178:8 4.Risitano,AM;Paroxysmalnocturnalhemoglobinuriaandothercomplement-mediatedhematologicaldisorders.ImmunoBIOLOGy2012,217:11 5.Lindorfer,Metal;Anovelapproachtopreventingthehemolysisofparoxysmalnocturnalhemoglobinuria:bothcomplement-mediatedcytolysisandC3depositionareblockedbyamonoclonalantibodyspecificforthealternativepathwayofcomplement.Blood2010,115:11 6.DiLillo,Detal;SelectiveandefficientinhibitionofthealternativepathwayofcomplementbyamAbthatrecognizesC3b/iC3b.MolecularImmunology2006,43:7 7.Paixão-Cavalvante,Detal;Ahumanizedantibodythatregulatesthealternativepathwayconvertase:Potentialfortherapyofrenaldiseaseassociatedwithnephriticfactors.JournalofImmunology2014,192:10 8.Beum,Petal;ComplementactivationonBlymphocytesopsonizedwithrituximaborofatumumabproducessubstantialchangesinmembranestructureprecedingcelllysis.Journalofimmunology2008,181:1 |
| StorageandstABIlity | Productshouldbestoredat4°C.Underrecommendedstorageconditions,productisstableforatleastoneyear.Theexactexpirydateisindicatedonthelabel. |
| Precautions | Forresearchuseonly.Notforuseinoronhumansoranimalsorfordiagnostics.Itistheresponsibilityoftheusertocomplywithalllocal/stateandfederalrulesintheuseofthisproduct.HycultBiotechisnotresponsIBLeforanypatentinfringementsthatmightresultfromtheuseorderivationofthisproduct. |
| Disease | Infectiousdiseases,Nephrology |
品牌介绍
荷兰HyCult Biotechnology(HBT)位于荷兰乌登，从1994开始制造检测抗体和蛋白质，主要侧重与病理学诊断有关的全套产品研发，既有纯化的重组蛋白和多肽，也有单抗和多抗，是世界一流的先天免疫领域的研究试剂制造商。
联络我们
